Page 56 - 《南京医科大学学报（自然科学版）》2026年第3期

第46卷第3期
·364 · 南 京 医 科 大 学 学 报 2026年3月

thymic clonal deletion at the population level［J］. J Immu⁃ ［39］PADDA S K，YAO X P，ANTONICELLI A，et al. Paraneo⁃
nol，2019，202（11）：3226-3233 plastic syndromes and thymic malignancies：an examina⁃
［26］BOUILLET P，PURTON J F，GODFREY D I，et al. BH3⁃ tion of the international thymic malignancy interest group
only Bcl⁃2 family member Bim is required for apoptosis of retrospective database［J］. J Thorac Oncol，2018，13（3）：
autoreactive thymocytes［J］. Nature，2002，415（6874）： 436-446
922-926 ［40］BALLMAN M，ZHAO C，MCADAMS M J，et al. Immuno⁃
［27］ TOOMER K H，MALEK T R. Cytokine signaling in the therapy for management of thymic epithelial tumors：a
development and homeostasis of regulatory T cells［J］. double ⁃ edged sword［J］. Cancers（Basel），2022，14（9）：
Cold Spring Harb Perspect Biol，2018，10（3）：a028597 2060
［28］LIO C J，HSIEH C S. A two⁃step process for thymic regu⁃ ［41］LIPPNER E A，LEWIS D B，ROBINSON W H，et al. Para⁃
latory T cell development［J］. Immunity，2008，28（1）： neoplastic and therapy⁃related immune complications in
100-111 thymic malignancies［J］. Curr Treat Options Oncol，2019，
［29］APERT C，GALINDO⁃ALBARRÁN A O，CASTAN S，et 20（7）：62
al. IL ⁃ 2 and IL ⁃ 15 drive intrathymic development of ［42］ISHIHARA S，OKADA S，OGI H，et al. Programmed death⁃
+
distinct periphery ⁃ seeding CD4 Foxp3 + regulatory T ligand 1 expression profiling in thymic epithelial cell
lymphocytes［J］. Front Immunol，2022，13：965303 tumors：clinicopathological features and quantitative digi⁃
［30］FAN M Y，TURKA L A. Immunometabolism and PI（3）K tal image analyses［J］. Lung Cancer，2020，145：40-47
signaling as a link between IL⁃2，Foxp3 expression，and ［43］RAJAN A，HEERY C R，THOMAS A，et al. Efficacy and
suppressor function in regulatory T cells［J］. Front Immu⁃ tolerability of anti⁃programmed death⁃ligand 1（PD⁃L1）
nol，2018，9：69 antibody（Avelumab）treatment in advanced thymoma［J］.
［31］SMITH J A，YUEN B T K，PURTHA W，et al. Aire medi⁃ J Immunother Cancer，2019，7（1）：269
ates tolerance to insulin through thymic trimming of high⁃ ［44］National Cancer Institute. A pilot study to investigate the
affinity T cell clones［J］. Proc Natl Acad Sci USA，2024， safety and clinical activity of avelumab（MSB0010718C）
121（20）：e2320268121 in thymoma and thymic carcinoma after progression on
［32］ ZHAO S J，DING J Q，WANG S Y，et al. Decreased platinum-based chemotherapy［EB/OL］.（2025-10-20）
expression of circulating AIRE and increased Tfh/Tfr ［2025-10-25］. https：//clinicaltrials.gov/study/NCT03076
cells in myasthenia gravis patients［J］. Biosci Rep，2018， 554

38（6）：BSR20180096 ［45］BRACCI L，SCHIAVONI G，SISTIGU A，et al. Immune⁃
［33］FERNANDO R，LU Y，ATKINS S J，et al. Expression of based mechanisms of cytotoxic chemotherapy：implica⁃
thyrotropin receptor，thyroglobulin，sodium ⁃ iodide sym⁃ tions for the design of novel and rationale⁃based combined
porter，and thyroperoxidase by fibrocytes depends on treatments against cancer［J］. Cell Death Differ，2014，21
AIRE［J］. J Clin Endocrinol Metab，2014，99（7）：E1236- （1）：15-25
E1244 ［46］CONFORTI F，ZUCALI P A，PALA L，et al. Avelumab
［34］MATHIS D，BENOIST C. A decade of AIRE［J］. Nat Rev plus axitinib in unresectable or metastatic type B3 thymo⁃
Immunol，2007，7（8）：645-650 mas and thymic carcinomas（CAVEATT）：a single⁃arm，
［35］TATEO V，MANUZZI L，DE GIGLIO A，et al. Immunobio⁃ multicentre，phase 2 trial［J］. Lancet Oncol，2022，23
logy of thymic epithelial tumors：implications for immuno⁃ （10）：1287-1296
therapy with immune checkpoint inhibitors［J］. Int J Mol ［47］REMON J，GIRARD N，NOVELLO S，et al. PECATI：a
Sci，2020，21（23）：9056 multicentric，open ⁃ label，single ⁃ arm phase Ⅱ study to
［36］LIU Y M，ZHANG H，ZHANG P，et al. Autoimmune regu⁃ evaluate the efficacy and safety of pembrolizumab and
lator expression in thymomas with or without autoimmune lenvatinib in pretreated B3⁃thymoma and thymic carcino⁃
disease［J］. Immunol Lett，2014，161（1）：50-56 ma patients［J］. Clin Lung Cancer，2022，23（3）：e243-e246
［37］AO Y Q，GAO J，WANG S，et al. Immunotherapy of thymic ［48］REMON J，BIRONZO P，GIRARD N，et al. Lenvatinib
epithelial tumors：molecular understandings and clinical plus pembrolizumab in pretreated metastatic B3 thymoma
perspectives［J］. Mol Cancer，2023，22（1）：70 and thymic carcinoma（PECATI）：a single⁃arm，phase 2
［38］ RADOVICH M，PICKERING C R，FELAU I，et al. The trial［J］. Lancet Oncol，2025，26（9）：1215-1226
integrated genomic landscape of thymic epithelial tu⁃ ［49］KON E，BENHAR I. Immune checkpoint inhibitor combi⁃
mors［J］. Cancer Cell，2018，33（2）：244-258 nations：Current efforts and important aspects for suc⁃